Discrepancy between Tumor Size Assessed by Full-Field Digital Mammography or Ultrasonography (cT) and Pathology (pT) in a Multicenter Series of Breast Metaplastic Carcinoma Patients
Metaplastic breast cancer (BC-Mp) presents diagnostic and therapeutic complexities, with scant literature available. Correct assessment of tumor size by ultrasound (US) and full-field digital mammography (FFDM) is crucial for treatment planning. A retrospective cohort study was conducted on database...
Gespeichert in:
| Veröffentlicht in: | Cancers 2023-12, Vol.16 (1), p.188 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 188 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Püsküllüoğlu, Mirosława Świderska, Katarzyna Konieczna, Aleksandra Rudnicki, Wojciech Pacholczak-Madej, Renata Kunkiel, Michał Grela-Wojewoda, Aleksandra Mucha-Małecka, Anna Mituś, Jerzy W Stobiecka, Ewa Ryś, Janusz Jarząb, Michał Ziobro, Marek |
| description | Metaplastic breast cancer (BC-Mp) presents diagnostic and therapeutic complexities, with scant literature available. Correct assessment of tumor size by ultrasound (US) and full-field digital mammography (FFDM) is crucial for treatment planning.
A retrospective cohort study was conducted on databases encompassing records of BC patients (2012-2022) at the National Research Institutes of Oncology (Warsaw, Gliwice and Krakow Branches). Inclusion criteria comprised confirmed diagnosis in postsurgical pathology reports with tumor size details (pT) and availability of tumor size from preoperative US and/or FFDM. Patients subjected to neoadjuvant systemic treatment were excluded. Demographics and clinicopathological data were gathered.
Forty-five females were included. A total of 86.7% were triple-negative. The median age was 66 years (range: 33-89). The median pT was 41.63 mm (6-130), and eight patients were N-positive. Median tumor size assessed by US and FFDM was 31.81 mm (9-100) and 34.14 mm (0-120), respectively. Neither technique demonstrated superiority (
> 0.05), but they both underestimated the tumor size (
= 0.002 for US and
= 0.018 for FFDM). Smaller tumors (pT1-2) were statistically more accurately assessed by any technique (
< 0.001). Only pT correlated with overall survival.
The risk of underestimation in tumor size assessment with US and FFDM has to be taken into consideration while planning surgical procedures for BC-Mp. |
| doi_str_mv | 10.3390/cancers16010188 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10778481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2912534572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-bc252a3ad79d5fc73bae49e3ee57174d9d90038614ba2846b5a528d56d834e113</originalsourceid><addsrcrecordid>eNpdUstu1DAUjRCIVqVrdsgSm7IYGj9iOytUpgwgdQQS03V0Y9-ZceXEwU5Aw3_xfzjqQ6WWJV8dn3PuQ7coXtPyPed1eW6gNxgTlSUtqdbPimNWKraQshbPH8VHxWlKN2U-nFMl1cviiGtWUkmr4-LvpUsm4pCtDqTF8TdiTzZTFyL54f4guUgJ87WkPZDV5P1i5dBbcul2bgRP1tB1YRdh2B9Illz7MUIK_T10ZjbvCPSWfIdxH3zYZWjIkOsJkPXkR2ewHzHnwugwkbAlHyNCGskaRxh8jpwhS4jG9aGD2cZlQXpVvNiCT3h6954U16tPm-WXxdW3z1-XF1cLw5UcF61hFQMOVtW22hrFW0BRI0esFFXC1rbOQ9GSihaYFrKtoGLaVtJqLpBSflJ8uPUdprZDOxcbwTdDdB3EQxPANf__9G7f7MKvhpZKaaFnh7M7hxh-TpjGpssDR--hxzClhtWUC6G0VJn69gn1Jkyxz_3NLFZxUSmWWee3LBNDShG3D9XQspnXonmyFlnx5nETD_z7JeD_AHaTt1U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2912534572</pqid></control><display><type>article</type><title>Discrepancy between Tumor Size Assessed by Full-Field Digital Mammography or Ultrasonography (cT) and Pathology (pT) in a Multicenter Series of Breast Metaplastic Carcinoma Patients</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Püsküllüoğlu, Mirosława ; Świderska, Katarzyna ; Konieczna, Aleksandra ; Rudnicki, Wojciech ; Pacholczak-Madej, Renata ; Kunkiel, Michał ; Grela-Wojewoda, Aleksandra ; Mucha-Małecka, Anna ; Mituś, Jerzy W ; Stobiecka, Ewa ; Ryś, Janusz ; Jarząb, Michał ; Ziobro, Marek</creator><creatorcontrib>Püsküllüoğlu, Mirosława ; Świderska, Katarzyna ; Konieczna, Aleksandra ; Rudnicki, Wojciech ; Pacholczak-Madej, Renata ; Kunkiel, Michał ; Grela-Wojewoda, Aleksandra ; Mucha-Małecka, Anna ; Mituś, Jerzy W ; Stobiecka, Ewa ; Ryś, Janusz ; Jarząb, Michał ; Ziobro, Marek</creatorcontrib><description>Metaplastic breast cancer (BC-Mp) presents diagnostic and therapeutic complexities, with scant literature available. Correct assessment of tumor size by ultrasound (US) and full-field digital mammography (FFDM) is crucial for treatment planning.
A retrospective cohort study was conducted on databases encompassing records of BC patients (2012-2022) at the National Research Institutes of Oncology (Warsaw, Gliwice and Krakow Branches). Inclusion criteria comprised confirmed diagnosis in postsurgical pathology reports with tumor size details (pT) and availability of tumor size from preoperative US and/or FFDM. Patients subjected to neoadjuvant systemic treatment were excluded. Demographics and clinicopathological data were gathered.
Forty-five females were included. A total of 86.7% were triple-negative. The median age was 66 years (range: 33-89). The median pT was 41.63 mm (6-130), and eight patients were N-positive. Median tumor size assessed by US and FFDM was 31.81 mm (9-100) and 34.14 mm (0-120), respectively. Neither technique demonstrated superiority (
> 0.05), but they both underestimated the tumor size (
= 0.002 for US and
= 0.018 for FFDM). Smaller tumors (pT1-2) were statistically more accurately assessed by any technique (
< 0.001). Only pT correlated with overall survival.
The risk of underestimation in tumor size assessment with US and FFDM has to be taken into consideration while planning surgical procedures for BC-Mp.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16010188</identifier><identifier>PMID: 38201615</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Breast cancer ; Breast carcinoma ; Computed tomography ; Ethics ; Histopathology ; Lymphatic system ; Mammography ; Medical prognosis ; Mortality ; Oncology ; Pathology ; Patients ; Research centers ; Statistical analysis ; Tumors ; Ultrasonic imaging ; Ultrasound</subject><ispartof>Cancers, 2023-12, Vol.16 (1), p.188</ispartof><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c376t-bc252a3ad79d5fc73bae49e3ee57174d9d90038614ba2846b5a528d56d834e113</cites><orcidid>0000-0003-2168-5638 ; 0000-0002-6727-8926 ; 0000-0002-2647-9625 ; 0000-0002-2642-9724 ; 0000-0002-6535-4841</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10778481/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10778481/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38201615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Püsküllüoğlu, Mirosława</creatorcontrib><creatorcontrib>Świderska, Katarzyna</creatorcontrib><creatorcontrib>Konieczna, Aleksandra</creatorcontrib><creatorcontrib>Rudnicki, Wojciech</creatorcontrib><creatorcontrib>Pacholczak-Madej, Renata</creatorcontrib><creatorcontrib>Kunkiel, Michał</creatorcontrib><creatorcontrib>Grela-Wojewoda, Aleksandra</creatorcontrib><creatorcontrib>Mucha-Małecka, Anna</creatorcontrib><creatorcontrib>Mituś, Jerzy W</creatorcontrib><creatorcontrib>Stobiecka, Ewa</creatorcontrib><creatorcontrib>Ryś, Janusz</creatorcontrib><creatorcontrib>Jarząb, Michał</creatorcontrib><creatorcontrib>Ziobro, Marek</creatorcontrib><title>Discrepancy between Tumor Size Assessed by Full-Field Digital Mammography or Ultrasonography (cT) and Pathology (pT) in a Multicenter Series of Breast Metaplastic Carcinoma Patients</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Metaplastic breast cancer (BC-Mp) presents diagnostic and therapeutic complexities, with scant literature available. Correct assessment of tumor size by ultrasound (US) and full-field digital mammography (FFDM) is crucial for treatment planning.
A retrospective cohort study was conducted on databases encompassing records of BC patients (2012-2022) at the National Research Institutes of Oncology (Warsaw, Gliwice and Krakow Branches). Inclusion criteria comprised confirmed diagnosis in postsurgical pathology reports with tumor size details (pT) and availability of tumor size from preoperative US and/or FFDM. Patients subjected to neoadjuvant systemic treatment were excluded. Demographics and clinicopathological data were gathered.
Forty-five females were included. A total of 86.7% were triple-negative. The median age was 66 years (range: 33-89). The median pT was 41.63 mm (6-130), and eight patients were N-positive. Median tumor size assessed by US and FFDM was 31.81 mm (9-100) and 34.14 mm (0-120), respectively. Neither technique demonstrated superiority (
> 0.05), but they both underestimated the tumor size (
= 0.002 for US and
= 0.018 for FFDM). Smaller tumors (pT1-2) were statistically more accurately assessed by any technique (
< 0.001). Only pT correlated with overall survival.
The risk of underestimation in tumor size assessment with US and FFDM has to be taken into consideration while planning surgical procedures for BC-Mp.</description><subject>Breast cancer</subject><subject>Breast carcinoma</subject><subject>Computed tomography</subject><subject>Ethics</subject><subject>Histopathology</subject><subject>Lymphatic system</subject><subject>Mammography</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Patients</subject><subject>Research centers</subject><subject>Statistical analysis</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><subject>Ultrasound</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdUstu1DAUjRCIVqVrdsgSm7IYGj9iOytUpgwgdQQS03V0Y9-ZceXEwU5Aw3_xfzjqQ6WWJV8dn3PuQ7coXtPyPed1eW6gNxgTlSUtqdbPimNWKraQshbPH8VHxWlKN2U-nFMl1cviiGtWUkmr4-LvpUsm4pCtDqTF8TdiTzZTFyL54f4guUgJ87WkPZDV5P1i5dBbcul2bgRP1tB1YRdh2B9Illz7MUIK_T10ZjbvCPSWfIdxH3zYZWjIkOsJkPXkR2ewHzHnwugwkbAlHyNCGskaRxh8jpwhS4jG9aGD2cZlQXpVvNiCT3h6954U16tPm-WXxdW3z1-XF1cLw5UcF61hFQMOVtW22hrFW0BRI0esFFXC1rbOQ9GSihaYFrKtoGLaVtJqLpBSflJ8uPUdprZDOxcbwTdDdB3EQxPANf__9G7f7MKvhpZKaaFnh7M7hxh-TpjGpssDR--hxzClhtWUC6G0VJn69gn1Jkyxz_3NLFZxUSmWWee3LBNDShG3D9XQspnXonmyFlnx5nETD_z7JeD_AHaTt1U</recordid><startdate>20231230</startdate><enddate>20231230</enddate><creator>Püsküllüoğlu, Mirosława</creator><creator>Świderska, Katarzyna</creator><creator>Konieczna, Aleksandra</creator><creator>Rudnicki, Wojciech</creator><creator>Pacholczak-Madej, Renata</creator><creator>Kunkiel, Michał</creator><creator>Grela-Wojewoda, Aleksandra</creator><creator>Mucha-Małecka, Anna</creator><creator>Mituś, Jerzy W</creator><creator>Stobiecka, Ewa</creator><creator>Ryś, Janusz</creator><creator>Jarząb, Michał</creator><creator>Ziobro, Marek</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2168-5638</orcidid><orcidid>https://orcid.org/0000-0002-6727-8926</orcidid><orcidid>https://orcid.org/0000-0002-2647-9625</orcidid><orcidid>https://orcid.org/0000-0002-2642-9724</orcidid><orcidid>https://orcid.org/0000-0002-6535-4841</orcidid></search><sort><creationdate>20231230</creationdate><title>Discrepancy between Tumor Size Assessed by Full-Field Digital Mammography or Ultrasonography (cT) and Pathology (pT) in a Multicenter Series of Breast Metaplastic Carcinoma Patients</title><author>Püsküllüoğlu, Mirosława ; Świderska, Katarzyna ; Konieczna, Aleksandra ; Rudnicki, Wojciech ; Pacholczak-Madej, Renata ; Kunkiel, Michał ; Grela-Wojewoda, Aleksandra ; Mucha-Małecka, Anna ; Mituś, Jerzy W ; Stobiecka, Ewa ; Ryś, Janusz ; Jarząb, Michał ; Ziobro, Marek</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-bc252a3ad79d5fc73bae49e3ee57174d9d90038614ba2846b5a528d56d834e113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Breast cancer</topic><topic>Breast carcinoma</topic><topic>Computed tomography</topic><topic>Ethics</topic><topic>Histopathology</topic><topic>Lymphatic system</topic><topic>Mammography</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Patients</topic><topic>Research centers</topic><topic>Statistical analysis</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><topic>Ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Püsküllüoğlu, Mirosława</creatorcontrib><creatorcontrib>Świderska, Katarzyna</creatorcontrib><creatorcontrib>Konieczna, Aleksandra</creatorcontrib><creatorcontrib>Rudnicki, Wojciech</creatorcontrib><creatorcontrib>Pacholczak-Madej, Renata</creatorcontrib><creatorcontrib>Kunkiel, Michał</creatorcontrib><creatorcontrib>Grela-Wojewoda, Aleksandra</creatorcontrib><creatorcontrib>Mucha-Małecka, Anna</creatorcontrib><creatorcontrib>Mituś, Jerzy W</creatorcontrib><creatorcontrib>Stobiecka, Ewa</creatorcontrib><creatorcontrib>Ryś, Janusz</creatorcontrib><creatorcontrib>Jarząb, Michał</creatorcontrib><creatorcontrib>Ziobro, Marek</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Püsküllüoğlu, Mirosława</au><au>Świderska, Katarzyna</au><au>Konieczna, Aleksandra</au><au>Rudnicki, Wojciech</au><au>Pacholczak-Madej, Renata</au><au>Kunkiel, Michał</au><au>Grela-Wojewoda, Aleksandra</au><au>Mucha-Małecka, Anna</au><au>Mituś, Jerzy W</au><au>Stobiecka, Ewa</au><au>Ryś, Janusz</au><au>Jarząb, Michał</au><au>Ziobro, Marek</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discrepancy between Tumor Size Assessed by Full-Field Digital Mammography or Ultrasonography (cT) and Pathology (pT) in a Multicenter Series of Breast Metaplastic Carcinoma Patients</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-12-30</date><risdate>2023</risdate><volume>16</volume><issue>1</issue><spage>188</spage><pages>188-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Metaplastic breast cancer (BC-Mp) presents diagnostic and therapeutic complexities, with scant literature available. Correct assessment of tumor size by ultrasound (US) and full-field digital mammography (FFDM) is crucial for treatment planning.
A retrospective cohort study was conducted on databases encompassing records of BC patients (2012-2022) at the National Research Institutes of Oncology (Warsaw, Gliwice and Krakow Branches). Inclusion criteria comprised confirmed diagnosis in postsurgical pathology reports with tumor size details (pT) and availability of tumor size from preoperative US and/or FFDM. Patients subjected to neoadjuvant systemic treatment were excluded. Demographics and clinicopathological data were gathered.
Forty-five females were included. A total of 86.7% were triple-negative. The median age was 66 years (range: 33-89). The median pT was 41.63 mm (6-130), and eight patients were N-positive. Median tumor size assessed by US and FFDM was 31.81 mm (9-100) and 34.14 mm (0-120), respectively. Neither technique demonstrated superiority (
> 0.05), but they both underestimated the tumor size (
= 0.002 for US and
= 0.018 for FFDM). Smaller tumors (pT1-2) were statistically more accurately assessed by any technique (
< 0.001). Only pT correlated with overall survival.
The risk of underestimation in tumor size assessment with US and FFDM has to be taken into consideration while planning surgical procedures for BC-Mp.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38201615</pmid><doi>10.3390/cancers16010188</doi><orcidid>https://orcid.org/0000-0003-2168-5638</orcidid><orcidid>https://orcid.org/0000-0002-6727-8926</orcidid><orcidid>https://orcid.org/0000-0002-2647-9625</orcidid><orcidid>https://orcid.org/0000-0002-2642-9724</orcidid><orcidid>https://orcid.org/0000-0002-6535-4841</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-12, Vol.16 (1), p.188 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10778481 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Breast cancer Breast carcinoma Computed tomography Ethics Histopathology Lymphatic system Mammography Medical prognosis Mortality Oncology Pathology Patients Research centers Statistical analysis Tumors Ultrasonic imaging Ultrasound |
| title | Discrepancy between Tumor Size Assessed by Full-Field Digital Mammography or Ultrasonography (cT) and Pathology (pT) in a Multicenter Series of Breast Metaplastic Carcinoma Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A27%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discrepancy%20between%20Tumor%20Size%20Assessed%20by%20Full-Field%20Digital%20Mammography%20or%20Ultrasonography%20(cT)%20and%20Pathology%20(pT)%20in%20a%20Multicenter%20Series%20of%20Breast%20Metaplastic%20Carcinoma%20Patients&rft.jtitle=Cancers&rft.au=P%C3%BCsk%C3%BCll%C3%BCo%C4%9Flu,%20Miros%C5%82awa&rft.date=2023-12-30&rft.volume=16&rft.issue=1&rft.spage=188&rft.pages=188-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16010188&rft_dat=%3Cproquest_pubme%3E2912534572%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2912534572&rft_id=info:pmid/38201615&rfr_iscdi=true |